Document is current
Any future updates will be listed below
-
Authors
Minarik, Jiri
Pour, Ludek
Latal, Vojtech
Jelinek, Tomas
Straub, Jan
Jungova, Alexandra
Radocha, Jakub
Pavlicek, Petr
Stork, Martin
Pika, Tomas
Krhovska, Petra
Popkova, Tereza
Sedlak, Frantisek
Spicka, Ivan
Jindra, Pavel
Capounova, Vladimira
Maisnar, Vladimir
Hajek, Roman
- License Information
-
More Information
Article History
Received: 11 February 2025
Accepted: 4 April 2025
First Online: 9 April 2025
Declarations
:
: The ethical committees of participating Institutions approved the informed consent and inclusion of patients into the Registry of Monoclonal Gammopathies. The overal study was approved by the Ethics comittee of University Hospital Olomouc:Etická komise FNOL a LF UPZdravotníků 248/7779 00 OlomoucCzech Republic
: Not applicable.
: JM had consultancy and received honoraria from Amgen, BMS, Celgene, GSK, Johnson & Johnson, Pfizer, Sanofi, Takeda. LP declares no conflict of interest; VL had consultancy and received honoraria from Sanofi; TJ had consultancy and recieved honoraria or research funding from Amgen, Johnson & Johnson, Sanofi, Pfizer, BMS, GSK. JS had consultancy and received honoraria from Amgen, BMS, Celgene, GSK, Johnson & Johnson, Sanofi; AJ declares no conflict of interest; JR had consultancy and received honoraria from Amgen, BMS, GSK, Johnson & Johnson, Pfizer and Sanofi; PP had consultancy and received honoraria from Amgen, BMS, Celgene, GSK, Johnson & Johnson, Pfizer, Sanofi, Takeda, MS had consultancy and received honoraria from Johnson & Johnson, Pfizer, Sanofi; TP declares no conflict of interest; PK had consultancy and received honoraria from Amgen and Sanofi; TP received honoraria from Johnson&Johnson and Takeda. FS declares no conflict of interest; IS had consultancy/advisory role and received honoraria from Amgen, BMS, GSK, Pfizer, Johnson & Johnson, Sanofi,PJ had consultancy and received honoraria from AstraZeneca, BMS, GSK, Johnson & Johnson, Pfizer, AbbVie, Takeda, Novartis.; VC declares no conflict of interest; VM had consultancy/advisory role and received honoraria from Amgen, BMS, GSK, Pfizer, Johnson & Johnson, Sanofi, The Binding Site.; RH has had a consultant or advisory relationship with Janssen, Amgen, Celgene, AbbVie, BMS, Novartis, PharmaMar, and Takeda; has received honoraria from Janssen, Amgen, Celgene, BMS, PharmaMar, and Takeda; has received research funding from Janssen, Amgen, Celgene, BMS, Novartis, and Takeda.
